Design, Synthesis, and Anti-Breast Cancer Activity of Novel Fluorinated 7- O-Modified Genistein Derivatives

Med Chem. 2022;19(1):64-74. doi: 10.2174/1573406418666220607140651.

Abstract

Background: Genistein has been limited in clinical application due to its low bioavailability, extremely poor liposolubility, and fast glycosylation rate, though it possesses anti-breast cancer activity. Therefore, the discovery of novel genistein derivatives is an urgency.

Objective: To enhance the anti-breast cancer activity of genistein, a series of novel fluorinated genistein derivatives were synthesized.

Methods: Their in vitro antitumor activity was investigated by the MTT assay against three cancer cell lines, via, MDA-MB-231, MCF-7, and MDA-MB-435, respectively.

Results: Analogs 1d, 2b, and 3b showed remarkable anticancer activities compared to tamoxifen, a clinical anti-breast cancer drug on the market.

Conclusion: The activities against breast cancer of genistein were enhanced by introducing the 7- alkoxyl group and fluorine atom into the B-ring. Therefore, these compounds may be potential candidates for treating breast cancer.

Keywords: Anti-breast cancer activities; MTT assay; baker-venkataraman reaction; fluorinated-genistein derivatives; genistein; structure-activity relationship..

MeSH terms

  • Antineoplastic Agents*
  • Breast Neoplasms* / pathology
  • Cell Line
  • Cell Line, Tumor
  • Cell Proliferation
  • Drug Screening Assays, Antitumor
  • Female
  • Genistein / pharmacology
  • Genistein / therapeutic use
  • Humans
  • Molecular Structure
  • Tamoxifen / pharmacology
  • Tamoxifen / therapeutic use

Substances

  • Genistein
  • Antineoplastic Agents
  • Tamoxifen